Synovex (Boston, MA), a clinical stage biotechnology company focused on inhibiting the progression of fibrotic diseases such as arthritis, closed a $3.5M Series C financing. Participants were not identified.

Neurovance (Cambridge, MA), a clinical stage pharmaceutical company developing a norepinephrine, dopamine and serotonin triple uptake inhibitor to treat ADHD, closed a $7M Series A financing. Participants include Novartis Venture Fund and H&Q Life Sciences Investors.

TransMedics (Andover, MA) a commercial-stage medical device company focused on organ preservation technologies for transplants, closed a $36M Series E financing. Participants include Abrams Capital, Flagship Ventures, Hercules Technology Growth Capital and Kleiner Perkins Caufield & Byers.

Rhythm Pharmaceuticals (Boston, MA), a clinical-stage biotechnology company focused on peptide therapeutics for metabolic disorders, closed an $8M Series B financings, bringing the total round to $33M. Participants include Pfizer Ventures, MPM Capital, New Enterprise Associates, Third Rock Ventures and Ipsen Ventures. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive [...]

Visterra (Cambridge, MA), a preclinical-stage biotechnology company focused on seasonal and pandemic influenza, closed a $13M Series A financing, bringing the total round to $26M. Participants include The Bill & Melinda Gates Foundation, Omega Funds, Polaris Venture Partners, Flagship Ventures and Lux Capital. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled [...]

Metamark Genetics (Cambridge, MA), a preclinical-stage molecular diagnostics company focused on cancer, closed a $13M Series B financing. Participants were not identified. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP Account Access HERE

Genocea Biosciences (Cambridge, MA), a clinical-stage biotechnology company focused on therapeutic and prophylactic vaccines for infectious diseases, closed a $30M Series C financing. Participants include Bill & Melinda Gates Foundation, Central Valley Fund, Johnson & Johnson Development Corp., Skyline Ventures, MP Healthcare Venture Management, Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga [...]

Healthrageous (Boston, MA), a commercial-stage Health IT provider of self-management solutions, closed a $6.5M Series B financing. Participants include North Bridge Venture Partners, Egan-Managed Capital and Long River Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Neurovance (Cambridge, MA), a clinical-stage pharmaceutical company focused on treatments for CNS disorders such as adult attention deficit hyperactivity disorder, closed a $7M Series A financing. Participants include Novartis Venture Fund. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP [...]

GnuBIO (Cambridge, MA), a developmental-stage medical device company focused on next-generation DNA sequencing, closed a $10M Series B financing. Participants were not identified. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Quantia Communications (Waltham, MA), a HealthIT company and maker of an online physician community and collaboration platform, has closed a $12M Series E. Participants include Fuse Capital. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Nuclea Biotechnologies (Pittsfield, MA) a commercial-stage diagnostic company focused on in vitro companion diagnostic assays based on gene and protein expression profiles and biomarkers associated with an individual’s tumor or specific disease state, closed a $3.4M Series B financing bringing the total round to $9.8M. Participants were not identified. Note: Closing out 1Q deals. Thanx [...]

4s3 Bioscience (Medford, MA) a preclinical-stage biotherapeutics company focused on developing genetics disease therapies for orphan neuromuscular disorders, closed a $20M Series A financing. Participants include KLP Enterprises. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.